Solu Therapeutics to Present First Preclinical Data of STX-0712 for the Treatment of Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia at ASH Annual Meeting

On December 2, 2024 Solu Therapeutics ("Solu Therapeutics" or "Solu"), a biotechnology company pioneering novel therapies to eliminate disease-driving cells in cancer, immunology, and other therapeutic areas, reported that it will present the first preclinical data on STX-0712, its novel CCR2-CyTAC (Chemokine Receptor Type 2 Cytotoxicity Targeting Chimera) for the treatment of chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML) (Press release, Solu Therapeutics, DEC 2, 2024, View Source [SID1234648734]). The data will be featured in two poster presentations at the American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting, being held December 7-10, 2024, in San Diego, California.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

STX-0712 is a CyTAC targeting the G-Protein Coupled Receptor (GPCR) CCR2, a selective marker expressed at high levels on malignant monocytes in these indications, which are key drivers in certain hematologic cancers. By targeting CCR2, STX-0712 is designed to selectively eliminate these malignant cells.

ASH Poster Presentation Details:

Abstract Title: Ex-Vivo Evaluation of STX-0712, a CCR2 Cytotoxicity Targeting Chimera (CCR2-CyTAC) for the treatment of Acute Myeloid Leukemia
Date: Saturday, December 7, 2024
Time: 5:30 PM-7:30 PM PT
Location: San Diego Convention Center, Halls G-H
Session: 604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Poster I
Abstract Number: 1380

Abstract Title: Preclinical Evaluation of STX-0712, a CCR2 Cytotoxicity Targeting Chimera (CCR2-CyTAC) for the treatment of Chronic Myelomonocytic Leukemia
Date: Sunday, December 8, 2024
Time: 6:00 PM-8:00 PM PT
Location: San Diego Convention Center, Halls G-H
Session: 604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Poster II
Abstract Number: 2771